Tauriga Sciences Inc. Commences 2nd and Much Larger Production Run of its Plant Based CBD Infused Gum Drop Product
May 15 2020 - 8:24AM
InvestorsHub NewsWire
Tauriga Sciences Inc.
Commences 2nd and Much Larger Production Run of its
Plant Based CBD Infused Gum Drop Product, Branded as:
Tauri-Gummies
The Company Utilizes Packaging for its
Tauri-Gummies™ Product, that is Both: Environmentally Friendly and
Child Proof
NEW YORK, NY -- May 15, 2020 -- InvestorsHub NewsWire -- Tauriga
Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating Company that
operates through the development, distribution, and licensing of
proprietary products as well as the evaluation of potential
acquisition opportunities and equity investments, today announced
that it has commenced its 2ndproduction run of its plant
based Cannabidiol (“CBD”) infused Gum Drop product, branded as:
Tauri-Gummies™. The initial production run was completed
during January 2020, for a total of 1,000 Units (“Jar” or
“Pack”). This 2ndproduction run, which is
expected to be completed within the next 2-3 weeks, will yield a
total of 2,200 Jars. Tauri-Gummies™ sales have been
consistently strong on the Company’s E-Commerce platform (www.taurigum.com). Each Jar of the
Company’s Tauri-Gummies™ product, has an established MSRP of
$24.99.
The Company’s Tauri-Gummies™ product is
Gelatin-Free and consists of 4 distinct Gum Drop flavors – Format:
1950s nostalgic style. These flavors are: Cherry (red),
Orange (orange), Lemon (yellow), and Lime
(green).
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please
visit our corporate website, for additional information, as well as
inquiries, at www.tauriga.com.
Complementary to the Company’s retail business, are
its two ongoing biotechnology initiatives. The first one
relates to the development of a Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed to help
patients that are subjected to ongoing chemotherapy
treatment). On March 18, 2020, the Company announced that it
filed a provisional U.S. patent application covering its
pharmaceutical grade version of Tauri-Gum™. The Patent, filed
with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS
OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one
relates to a collaboration agreement with Aegea Biotechnologies
Inc. for the co-development of a rapid, multiplexed, Novel
Coronavirus (COVID-19) test with superior sensitivity and
selectivity.
The Company is headquartered in New York City and
operates a regional office in Barcelona, Spain. In addition,
the Company operates a full time E-Commerce fulfillment center
located in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking
Statements
This press release contains certain
“forward-looking statements” as defined by the Private Securities
Litigation Reform Act of 1995 which represent management’s beliefs
and assumptions concerning future events. These forward-looking
statements are often indicated by using words such as “may,”
“will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or
plans, and may include statements regarding corporate objectives as
well as the attainment of certain corporate goals and milestones.
Forward-looking statements are based on present circumstances and
on management’s present beliefs with respect to events that have
not occurred, that may not occur, or that may occur with different
consequences or timing than those now assumed or anticipated.
Actual results may differ materially from those expressed
in forward looking statements due to known and unknown
risks and uncertainties, such as are not guarantees of general
economic and business conditions, the ability to successfully
develop and market products, consumer and business consumption
habits, the ability to consummate successful acquisition and
licensing transactions, fluctuations in exchange rates, and other
factors over which Tauriga has little or no control. Many of these
risks and uncertainties are discussed in greater detail in the
“Risk Factors” section of Tauriga’s Form 10-K and other filings
made from time to time with the Securities and Exchange Commission.
Such forward-looking statements are made only as of the date of
this release, and Tauriga assumes no obligation to update
forward-looking statements to reflect subsequent events or
circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024